Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.

Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ.

Cancer Immunol Res. 2018 Sep 12. doi: 10.1158/2326-6066.CIR-18-0309. [Epub ahead of print]

PMID:
30209061
2.

Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.

Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, Ilett EJ, Salmond RJ, Melcher A, Lorger M.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1540-E1549. doi: 10.1073/pnas.1714089115. Epub 2018 Jan 31.

3.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

4.

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA.

Int J Cancer. 2014 Mar 1;134(5):1091-101. doi: 10.1002/ijc.28450. Epub 2013 Sep 18.

5.

Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.

Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA.

Clin Cancer Res. 2011 May 1;17(9):2767-76. doi: 10.1158/1078-0432.CCR-10-3266. Epub 2011 Mar 9.

6.

The evolving role of dendritic cells in cancer therapy.

Ilett EJ, Prestwich RJ, Melcher AA.

Expert Opin Biol Ther. 2010 Mar;10(3):369-79. doi: 10.1517/14712590903559830. Review.

PMID:
20132058
7.

JX-594, a targeted oncolytic poxvirus for the treatment of cancer.

Merrick AE, Ilett EJ, Melcher AA.

Curr Opin Investig Drugs. 2009 Dec;10(12):1372-82. Review.

PMID:
19943208
8.

Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.

Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

J Immunol. 2009 Oct 1;183(7):4312-21. doi: 10.4049/jimmunol.0901074. Epub 2009 Sep 4.

9.

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9.

10.

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA.

Gene Ther. 2009 May;16(5):689-99. doi: 10.1038/gt.2009.29. Epub 2009 Mar 12.

11.

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.

Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2008 Nov 15;14(22):7358-66. doi: 10.1158/1078-0432.CCR-08-0831.

12.

The importance of the immune system in reovirus therapy.

Prestwich RJ, Ilett EJ, Steele L, Errington F.

Clin Oncol (R Coll Radiol). 2008 Dec;20(10):769. doi: 10.1016/j.clon.2008.08.004. Epub 2008 Sep 27. No abstract available.

PMID:
18824336
13.

The immune system--is it relevant to cancer development, progression and treatment?

Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, Melcher AA.

Clin Oncol (R Coll Radiol). 2008 Mar;20(2):101-12. Epub 2007 Nov 26. Review.

PMID:
18037277

Supplemental Content

Loading ...
Support Center